News & Views Published: July 2008 Imatinib buys time for brain after stroke Peter Rieckmann Nature Medicine 14, 712–713 (2008) Cite this article ...

Gene-testing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

A new FTC report claims that pharmacy benefit managers generated $7.3bn by marking up specialty generics used to treat diseases like cancer and HIV.